# Ecolab (ECL) Financial Model Free Excel 3-statement financial model and company analysis for Ecolab. - Canonical: https://finamodel.com/companies/ecolab - Industry: Chemicals - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/ECL.xlsx ## Model Purpose This financial model provides a comprehensive equity valuation and scenario planning tool for an equity research analyst covering Ecolab, focusing on the impact of volume growth, "value pricing" strategies, and operating margin expansion driven by the "One Ecolab" initiative and recent segment realignments. ## Company Overview Ecolab Inc. (ECL) is a global leader in water, hygiene, and infection prevention solutions and services. The company provides proprietary chemicals and dispensing equipment to industrial, hospitality, healthcare, and life sciences customers, supported by a massive direct field sales and service force. Business segments (based on the 2025 realignment): * Global Water (approx. 50% of revenue) * Global Institutional & Specialty (approx. 38% of revenue) * Global Pest Elimination (approx. 8% of revenue) * Global Life Sciences (approx. 4% of revenue) Ecolab operates a classic "razor and blade" business model. The company installs proprietary dispensing equipment at customer sites and generates recurring revenue through the sale of chemical consumables and ongoing service contracts. Its competitive position is dominant, ranking as the clear market leader in its core institutional and water treatment markets. Recent major events include the 2025 segment realignment (which elevated Life Sciences to a standalone segment and moved Healthcare into Institutional), the 2024 divestiture of the global surgical solutions business, and the 2025 acquisition of Ovivo Electronics for $1.8 billion to expand its ultra-pure water capabilities for semiconductor manufacturing. ## Revenue Deep Dive ### Global Water * **Segment name:** Global Water (includes Heavy Water, Light Water, and High-Tech) * **Revenue driver formula:** Prior Year Revenue x (1 + Volume Growth + Value Pricing Growth) * **Historical growth rate:** 3% to 5% organic CAGR * **Key growth levers and headwinds:** Driven by industrial production volumes, corporate sustainability goals (water conservation), and rapid growth in data centre cooling and semiconductor manufacturing (High-Tech). Headwinds include cyclical downturns in basic industries and paper. * **Pricing dynamics:** Contractual with heavy reliance on "value pricing" (passing through inflation via surcharges and structural price increases). * **Revenue recognition notes:** Consumables recognised upon delivery; service revenue recognised as performed. * **Seasonality:** Relatively stable, though industrial plant turnarounds can impact quarterly volumes. ### Global Institutional & Specialty * **Segment name:** Global Institutional & Specialty * **Revenue driver formula:** Number of Customer Locations x Average Revenue per Location * **Historical growth rate:** 4% to 6% CAGR * **Key growth levers and headwinds:** Driven by hospitality occupancy rates, restaurant footfall, and healthcare facility admissions. Labour shortages at customer sites drive demand for Ecolab's automated dispensing solutions. * **Pricing dynamics:** Highly competitive but sticky due to the high cost of failure (e.g. foodborne illness) relative to the low cost of the chemicals. * **Revenue recognition notes:** Primarily point-in-time for consumables. * **Seasonality:** Stronger in Q2 and Q3 due to peak summer travel and dining. ### Global Pest Elimination * **Segment name:** Global Pest Elimination * **Revenue driver formula:** Active Service Contracts x Annual Contract Value * **Historical growth rate:** 6% to 8% CAGR * **Key growth levers and headwinds:** Driven by commercial real estate footprint, food safety regulations, and digital pest monitoring adoption. * **Pricing dynamics:** Subscription-like service contracts with annual price escalators. * **Revenue recognition notes:** Recognised over time as services are rendered. * **Seasonality:** Higher pest activity in warmer months (Q2 and Q3 in the Northern Hemisphere). ### Global Life Sciences * **Segment name:** Global Life Sciences * **Revenue driver formula:** Biopharma Production Volume x Consumable Intensity * **Historical growth rate:** 8% to 12% CAGR * **Key growth levers and headwinds:** Driven by biopharmaceutical manufacturing growth, cleanroom standards, and the Purolite resin business. * **Pricing dynamics:** High-margin, highly specified products where price sensitivity is low due to regulatory validation requirements. * **Revenue recognition notes:** Point-in-time upon shipment. * **Seasonality:** Minimal seasonality. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Raw materials (petrochemicals, inorganic chemicals, packaging), direct manufacturing labour, freight and logistics, and depreciation of customer-sited dispensing equipment. * **Gross margin range:** 40.0% to 44.5% (44.5% achieved in 2025). * **Key input costs and commodity exposures:** Highly exposed to petrochemical derivatives and freight costs. * **How COGS scales with revenue:** Largely linear with volume, but gross margin percentage expands when value pricing outpaces raw material inflation. ### Operating Expenses * **R&D:** Approximately 1.5% to 2.0% of revenue. Covers chemical formulation, digital monitoring tools, and dispensing technology. * **SG&A:** Approximately 25.0% to 27.0% of revenue. This is heavily headcount-driven, supporting the massive global field sales and service force ("the Ecolab representative"). * **Depreciation & Amortisation:** Approximately 5.0% to 6.0% of revenue. Includes amortisation of acquired intangibles from serial M&A. * **Restructuring / one-time charges:** Frequent. The company regularly implements efficiency programmes (e.g. the "One Ecolab" initiative in 2024/2025). ### Margin Profile * **Gross margin:** 40.0% to 44.5%. * **Operating margin:** 14.0% to 18.7% (organic operating margin reached 18.7% in Q3 2025). Management targets a 20% operating margin by 2027. * **Net margin:** 10.0% to 13.0%. * **Margin trend:** Expanding. The company has successfully implemented value pricing to recover past inflationary pressures and is leveraging digital tools to improve field service productivity. ## Balance Sheet Structure * **Total assets:** Approximately $21 billion to $23 billion. * **Key asset categories:** Goodwill and intangible assets dominate the balance sheet due to historical acquisitions (Nalco, Purolite, Ovivo). * **Working capital profile:** * **Days Sales Outstanding (DSO):** 50 to 55 days. * **Days Inventory Outstanding (DIO):** 60 to 65 days. * **Days Payable Outstanding (DPO):** 70 to 75 days. * **Net working capital as % of revenue:** Approximately 10% to 12%. * **Working capital dynamic:** Positive working capital. Growth consumes cash, but the business is highly cash-generative overall. * **PP&E:** Includes manufacturing facilities and, uniquely, capitalised dispensing equipment placed at customer premises. * **Right-of-use assets:** Material but standard for a company with a large global footprint of leased warehouses and vehicle fleets. ## Capital Expenditure & Investment * **Capex as % of revenue:** 4.0% to 5.0%. * **Maintenance capex vs. growth capex:** Roughly 40% maintenance, 60% growth (including new customer equipment installations). * **Major capex programmes:** Investments in digital capabilities, AI-enabled monitoring, and expansion of Purolite manufacturing capacity. * **M&A pattern:** Serial acquirer. Mix of continuous bolt-on acquisitions and occasional transformational deals (e.g. the $1.8 billion Ovivo Electronics acquisition in 2025). ## Debt & Capital Structure * **Total debt:** Approximately $7.5 billion to $8.5 billion. * **Debt/EBITDA ratio:** Typically managed around 2.0x to 2.5x. * **Credit rating:** Investment grade (typically A- range). * **Key debt instruments:** Senior unsecured notes and a commercial paper programme for short-term liquidity. * **Interest rate profile:** Predominantly fixed-rate bonds with staggered maturities. * **Share repurchase programme:** Active. Used to offset dilution from stock-based compensation and return excess cash. * **Dividend policy:** 34 consecutive years of dividend increases. The 2025 dividend was $2.68 per share, representing a payout ratio of approximately 35%. ## Cash Flow Characteristics * **Operating cash flow conversion:** High. OCF / Net Income typically ranges from 1.2x to 1.4x ($3.0 billion OCF on $2.08 billion Net Income in 2025). * **Free cash flow margin:** 12.0% to 14.0% of revenue. * **Major non-cash items:** Significant depreciation and amortisation (due to M&A and customer equipment) and stock-based compensation. * **Working capital cash flow impact:** Modest use of cash during periods of high organic growth. * **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are generally aligned with the GAAP effective rate (around 18% to 20%), though geographic mix causes slight variations. ## Sheet Structure 1. **Assumptions**: Hardcoded inputs for macroeconomic drivers, segment growth rates, pricing assumptions, margin targets, and capital allocation. 2. **Revenue Build**: Detailed build for the four realigned segments (Global Water, Global Institutional & Specialty, Global Pest Elimination, Global Life Sciences) separating volume and price. 3. **Income Statement**: GAAP and Adjusted views. Must include lines for special gains/charges to bridge reported to adjusted EPS. 4. **Balance Sheet**: Standard corporate format highlighting Goodwill, Intangibles, and Customer Equipment within PP&E. 5. **Cash Flow Statement**: Indirect method starting from Net Income, adjusting for D&A, working capital changes, and special charges. 6. **Working Capital Schedule**: DSO, DIO, DPO calculations driving the balance sheet and cash flow statement. 7. **Debt & Interest Schedule**: Tranche-by-tranche debt build, commercial paper balances, and interest expense calculation. 8. **Depreciation & Amortisation**: Waterfall schedule separating PP&E depreciation from acquisition-related intangible amortisation. 9. **DCF Valuation**: Unlevered free cash flow build, WACC calculation, terminal value, and implied share price. ## Key Financial Relationships 1. `Global Water Revenue = Prior Year Global Water Revenue * (1 + Water Volume Growth + Water Value Pricing)` 2. `Global Institutional & Specialty Revenue = Prior Year Institutional Revenue * (1 + Institutional Volume Growth + Institutional Value Pricing)` 3. `Total Revenue = Global Water Revenue + Global Institutional & Specialty Revenue + Global Pest Elimination Revenue + Global Life Sciences Revenue` 4. `Cost of Sales = Total Revenue * (1 - Consolidated Gross Margin %)` 5. `SG&A Expense = Total Revenue * SG&A Margin %` 6. `Segment Operating Income = Segment Revenue * Segment Operating Margin %` 7. `Adjusted Operating Income = Total Revenue - Cost of Sales - SG&A Expense` 8. `Reported Operating Income = Adjusted Operating Income - Special Charges - Restructuring Costs` 9. `Interest Expense = (Beginning Total Debt + Ending Total Debt) / 2 * Weighted Average Interest Rate` 10. `Adjusted Net Income = (Adjusted Operating Income - Interest Expense + Other Income) * (1 - Adjusted Effective Tax Rate)` 11. `Adjusted EPS = Adjusted Net Income / Diluted Shares Outstanding` 12. `Customer Equipment Capex = Total Revenue * Customer Equipment Capex %` ## Cross-Sheet Dependencies * The **Assumptions** sheet feeds all growth rates and margin targets into the **Revenue Build** and **Income Statement**. * The **Revenue Build** feeds the top line of the **Income Statement** and drives the **Working Capital Schedule**. * The **Income Statement** generates Net Income, which flows to the top of the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**. * The **Working Capital Schedule** calculates the change in NWC, which feeds the **Cash Flow Statement**. * The **Debt & Interest Schedule** calculates interest expense for the **Income Statement** and ending debt balances for the **Balance Sheet**. This creates a circular reference that requires a toggle switch to break. * The **Cash Flow Statement** determines the ending cash balance, which flows to the **Balance Sheet** to ensure it balances. ## Sign Convention * **Income Statement:** Revenues are positive. Expenses (COGS, SG&A, Interest, Taxes) are negative. * **Balance Sheet:** Assets are positive. Liabilities and Equity are positive. * **Cash Flow Statement:** Cash inflows are positive. Cash outflows (Capex, dividends, share repurchases, debt paydown) are negative. * **Calculations:** Gross Profit = Revenue + COGS (where COGS is negative). ## Things Most Likely to Go Wrong * **Segment Restatement:** Ecolab realigned its segments in 2025 (moving Healthcare to Institutional, elevating Life Sciences, and renaming Industrial to Water). Historical data prior to 2024 must be restated to match the new structure, or the model will break. * **Fixed vs. Public Currency:** Ecolab frequently reports organic growth in "fixed currency" to strip out FX impacts. The model must clearly distinguish between reported public currency revenue and fixed currency organic growth. * **Surgical Solutions Divestiture:** The August 2024 sale of the global surgical solutions business creates a 2% headwind to reported 2025 growth. The model must adjust the 2024 base to calculate true organic growth. * **Ovivo Acquisition Stub Period:** The 2025 acquisition of Ovivo Electronics requires pro-forma adjustments for the stub period to accurately forecast 2026 run-rate revenue in the Global Water segment. * **Special Charges:** Ecolab frequently reports "special gains and charges" (e.g. the One Ecolab initiative). Failing to separate these from core SG&A will distort the adjusted operating margin trajectory. * **Intangible Amortisation:** A significant portion of D&A is acquisition-related. Excluding this from adjusted earnings is standard practice for Ecolab; the model must separate tangible depreciation from intangible amortisation. * **Customer Equipment:** Dispensing equipment is capitalised and depreciated. Misclassifying this as a pure operating expense will understate EBITDA and overstate OCF. * **Margin Target Phasing:** Management targets a 20% operating margin by 2027. Hardcoding an immediate jump to 20% will overstate near-term cash flows; the model must phase this expansion gradually. ## Validation Checks * "Gross margin should be in the 43.0% to 45.0% range based on recent pricing actions; flag if outside this band." * "Operating margin should trend towards the 20.0% management target by 2027; flag if it exceeds 20.5%." * "Capex as % of revenue typically runs 4.0% to 5.0%; flag if it drops below 3.5%." * "OCF/Net Income conversion should be >1.2x; flag if cash conversion deteriorates." * "Debt/EBITDA should remain between 2.0x and 2.5x; flag if leverage exceeds 3.0x." * "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." * "Adjusted effective tax rate should be 18.0% to 20.0%; flag if outside this range." * "Dividend payout ratio should remain within 30% to 40% based on stated policy." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Global Water Revenue Growth | 4.5 | % | Midpoint of historical organic growth, boosted by High-Tech demand | | Global Institutional & Specialty Growth | 5.0 | % | Steady recovery and market share gains | | Global Pest Elimination Growth | 7.0 | % | Consistent high-single-digit historical performance | | Global Life Sciences Growth | 9.0 | % | High-growth end markets and Purolite expansion | | Consolidated Gross Margin | 44.5 | % | Matches actual 2025 reported adjusted gross margin | | SG&A as % of Revenue | 26.0 | % | Reflects ongoing productivity improvements from digital tools | | Effective Tax Rate | 19.4 | % | Matches actual 2025 adjusted tax rate | | Capex as % of Revenue | 4.5 | % | Historical average required to support customer equipment | | Days Sales Outstanding (DSO) | 52 | Days | Based on 2024/2025 working capital metrics | | Days Inventory Outstanding (DIO) | 62 | Days | Based on 2024/2025 working capital metrics | | Days Payable Outstanding (DPO) | 72 | Days | Based on 2024/2025 working capital metrics | | Average Interest Rate on Debt | 4.2 | % | Weighted average cost of existing fixed-rate debt | | Dividend per Share (Year 1) | 2.68 | $ | Actual 2025 declared dividend | | Share Repurchases | 500 | $M | Run-rate to offset dilution and return excess cash | | WACC | 7.5 | % | Standard discount rate for a large-cap, stable chemical/services business | | Terminal Growth Rate | 2.5 | % | Aligns with long-term global GDP and inflation expectations | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR (Ecolab Inc. Form 10-K, 10-Q, 8-K) and the Ecolab Investor Relations website. * **Key peers for benchmarking:** Diversey (now part of Solenis), Rollins (ROL - for Pest Elimination), Rentokil Initial (RTO - for Pest Elimination), Danaher (DHR - for Life Sciences/Water), and Xylem (XYL - for Water). * **Industry data sources:** STR (Smith Travel Research) for hospitality occupancy rates, National Restaurant Association for foodservice traffic, and semiconductor industry forecasts for High-Tech water demand. * **Consensus estimates:** FactSet or Bloomberg for forward-looking EPS and revenue consensus. ## Sources * Ecolab Inc. Form 10-K for the fiscal year ended December 31, 2024. * Ecolab Inc. Form 8-K (March 2026) detailing the 2025 segment realignment and fixed currency restatements. * Ecolab Inc. Q4 2025 and Full Year 2025 Earnings Release (February 2026). * Ecolab 2024 Growth & Impact Report. * Ecolab Investor Relations Presentations (2025/2026). --- ## Frequently asked questions ### What does Ecolab Inc. (ECL) do? Ecolab Inc. is a global leader in providing water, hygiene, and infection prevention solutions and services. The company supplies proprietary chemicals and dispensing equipment to various customers across industrial, hospitality, healthcare, and life sciences sectors. ### How does Ecolab generate its revenue? Ecolab operates a "razor and blade" business model, installing proprietary dispensing equipment at customer sites. Revenue is primarily generated through the recurring sale of chemical consumables and ongoing service contracts. ### What are the key capital expenditure assumptions for Ecolab's financial model? Capital expenditure for Ecolab is assumed to be between 4.0% and 5.0% of revenue in the financial model. This includes approximately 40% for maintenance and 60% for growth, such as new customer equipment installations and investments in digital capabilities. ### What is the purpose of the provided Ecolab financial model? This financial model serves as a comprehensive equity valuation and scenario planning tool for equity research analysts covering Ecolab. It focuses on analyzing the impact of volume growth, "value pricing" strategies, and operating margin expansion. ### Can I download an Excel financial model for Ecolab (ECL)? Yes, an Excel financial model for Ecolab (ECL) is available for download. This model provides a forecast horizon from FY2026 to FY2030, suitable for detailed equity analysis. ### What are Ecolab's main business segments? Ecolab's business segments, based on the 2025 realignment, include Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. These segments collectively cover the company's diverse offerings in water, hygiene, and infection prevention. [Interactive forecast calculator](https://finamodel.com/companies/ecolab/forecast)